… We examined the effect of dapagliflozin on correction of anaemia in patients with heart …
(HF) and reduced ejection fraction in DAPA-HF. We also analysed the effect of dapagliflozin on …

… The effect of dapagliflozin compared to placebo on each outcome was examined by means
… for HF and treatment-group assignment. We analysed the effect of dapagliflozin compared to …

… 15 We evaluated the effect of SGLT2 inhibition on … of dapagliflozin according to baseline
SBP, in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). …

… in DAPA-HF, we could not directly assess the potential incremental value of treatment with
both dapagliflozin … observed in both the PARADIGM-HF and DAPA-HF trials was on top of the …

Aims The aim of this study was to examine the effect of dapagliflozin on the incidence of
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …

… DAPA-HF trial, we observed that treatment with dapagliflozin … of cardiovascular death or
worsening HF, and its components, … the beneficial effects of dapagliflozin on HF outcomes are …

… standard treatment were eligible for DAPA-HF, which is comparing dapagliflozin 10 mg once
daily to … Overall, DAPA-HF patients were generally similar to those in recent registries and in …

… is to focus initially on the DAPA-HF study and its consequences and then to re-evaluate the
possible mechanisms of action of SGLT2 inhibitors considering that DAPA-HF results do not …

… death or worsening heart failure (HF) in patients who had HFrEF with and … effect of dapagliflozin
varied according to baseline renal function. We also examined the effect of dapagliflozin …

… failure (HF) hospitalization. We examined the frequency and significance of episodes of …
HF worsening, requiring the augmentation of oral therapy, and the effects of dapagliflozin on …